ArticleCureus2026
Dupilumab-Associated Ocular Surface Disease in a Local Asian Chinese Population.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis is a retrospective study evaluating the incidence, clinical characteristics, and risk factors of dupilumab-associated ocular surface disease (DAOSD) in a local Asian Chinese population. METHODOLOGY: A retrospective study of patients prescribed dupilumab for AD between January 2020 and May 2025 at a regional hospital. DAOSD was defined as new-onset ocular surface symptoms post-treatment. Statistical analysis included descriptive statistics, binary logistic regression (age, sex, scoring atopic dermatitis (SCORAD), treatment duration/dosage), and Fisher's exact test for categorical variables (IBM SPSS v22, IBM Corp., Armonk, NY).
resultsOf 43 included patients (mean age: <25 years, 83.7%; mean treatment duration: 418 days), 11 (25.6%) developed DAOSD (mean onset: 1.67 months). Symptoms were mild (itching, 8, 81.8%; redness, 5, 45.5%; dry eye, 4, 36.4%); 10 (90.9%) required only topical lubricants/antihistamines. No patients discontinued dupilumab due to DAOSD. Logistic regression showed no significant associations between DAOSD and age, sex, SCORAD, dosage, or duration (
conclusionsThe incidence of DAOSD in this Asian cohort was slightly lower than that in Caucasian populations, with predominantly mild symptoms. Prior allergic eye disease may confer protection against DAOSD, possibly due to prophylactic ocular therapies. Larger studies are needed to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.